ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ObsEva SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea
293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea
291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America
AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America
ABUS
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway
ABS

Talk to a Data Expert

Have a question? We'll get back to you promptly.